Post-earnings recap
Reported
Wed, Nov 8, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss of $0.22 per share, which was in line with expectations, but the lack of revenue figures and guidance contributed to a negative stock reaction. The stock fell by 6.93% as investors may have been concerned about the company's future prospects without clear direction from management. The focus remains on their clinical programs, but uncertainty remains high.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management appeared cautious about future performance, highlighting the importance of their ongoing clinical trials. There was no specific guidance provided for upcoming quarters.
Management did not provide specific guidance for future quarters.
The company emphasized ongoing efforts in its clinical programs.